Cargando…
Immunophenotypic signature of primary glioblastoma multiforme: A case of extended progression free survival
Glioblastoma-multiforme (GBM), the most aggressive glial tumor, has a worldwide age-adjusted incidence ranging from 0.59-3.69/100000 persons. Despite current multimodal-treatment approach, median-survival time and progression-free survival (PFS) remains short. Glioblastomas display a variety of mole...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480073/ https://www.ncbi.nlm.nih.gov/pubmed/28685138 http://dx.doi.org/10.12998/wjcc.v5.i6.247 |